JHM Biopharmaceutical has initiated the Phase III trial for recombinant botulinum neurotoxin of type A in treating upper limb spasticity in adults, with enrollment of the first patient completed.
Today, JHM Biopharmaceutical (Hangzhou) Co., Ltd. (here…